Sawhney R S, Hering T M, Sandell L J
Department of Medicine, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
J Biol Chem. 1991 May 15;266(14):9231-40.
We have studied the biosynthesis of cartilage dermatan sulfate proteoglycan II (DS-PGII) (decorin) using in vitro translation of mRNA to determine the size of the primary gene product and by radiolabeling the protein in the presence of tunicamycin to inhibit the addition of Asn-linked oligosaccharides. Pulse-chase experiments were performed to examine post-translational processing and secretion. Inhibitors of oligosaccharide processing were used to determine whether DS-PGII molecules containing partially processed oligosaccharides could become proteoglycans and be secreted. Cell-free translation of sucrose gradient-fractionated RNA and subsequent immunoprecipitation of the core protein confirmed that the functional translated mRNA is in the size range of the two mRNA species observed by hybridization of chondrocyte RNA with a bone PGII cloned probe and that the translation product is a single protein with an apparent molecular mass of 42 kDa. Digestion of the intact proteoglycan (average molecular mass = 103 kDa) with chondroitinase ABC or AC results in an approximately 48-49-kDa product. Chondrocytes treated with tunicamycin to inhibit Asn-linked oligosaccharide addition synthesize and secrete a glycosaminoglycan (GAG)-substituted proteoglycan (average molecular mass = 86 kDa), yielding a 42-kDa core protein after chondroitinase ABC digestion, showing that Asn-linked oligosaccharides are not required for the addition of GAG chains or secretion. Following a short pulse (10 min) of [3H]leucine, three glycosylated forms of the DS-PGII core protein were observed, one of which is likely to be the precursor form of PGII predicted by the implied protein sequence of both bovine and human cDNA clones. Following the apparent cleavage of the propeptide, GAG-substituted intracellular core protein is detectable. Susceptibility to endoglycosidase H indicates that approximately one-third of the secreted core protein contains exclusively complex-type Asn-linked oligosaccharides and approximately two-thirds contain high mannose as well as complex-type oligosaccharides. Secreted DS-PGII appears to be fully substituted with three Asn-linked oligosaccharide chains. Inhibitors of oligosaccharide processing, however, permitted secretion of GAG-substituted DS-PGII that was fully (three chains) or incompletely (one or two chains) substituted with partially processed Asn-linked carbohydrate chains. By comparison of chondrocyte DS-PGII with fibroblast DS-PGII, we conclude that the addition and processing of Asn-linked carbohydrate chains are directed by the amino acid sequence of the core protein. The results reported here also suggest that the addition of xylose, the initial step in GAG chain synthesis, occurs early in biosynthesis and is determined by the primary amino acid sequence of the core protein.(ABSTRACT TRUNCATED AT 400 WORDS)
我们利用mRNA的体外翻译来确定软骨硫酸皮肤素蛋白聚糖II(DS-PGII,饰胶蛋白聚糖)的初级基因产物大小,并通过在衣霉素存在的情况下对蛋白质进行放射性标记以抑制天冬酰胺连接的寡糖添加,从而对其生物合成进行了研究。进行脉冲追踪实验以检测翻译后加工和分泌过程。使用寡糖加工抑制剂来确定含有部分加工寡糖的DS-PGII分子是否能够成为蛋白聚糖并被分泌。对经蔗糖梯度分级分离的RNA进行无细胞翻译,随后对核心蛋白进行免疫沉淀,证实功能性翻译的mRNA处于软骨细胞RNA与骨PGII克隆探针杂交所观察到的两种mRNA种类的大小范围内,并且翻译产物是一种表观分子量为42 kDa的单一蛋白质。用软骨素酶ABC或AC消化完整的蛋白聚糖(平均分子量 = 103 kDa)会产生一种约48 - 49 kDa的产物。用衣霉素处理软骨细胞以抑制天冬酰胺连接的寡糖添加,可合成并分泌一种糖胺聚糖(GAG)取代的蛋白聚糖(平均分子量 = 86 kDa),经软骨素酶ABC消化后产生一个42 kDa的核心蛋白,这表明添加GAG链或分泌并不需要天冬酰胺连接的寡糖。在短时间脉冲(10分钟)加入[³H]亮氨酸后,观察到DS-PGII核心蛋白的三种糖基化形式,其中一种可能是牛和人cDNA克隆的隐含蛋白质序列所预测的PGII前体形式。在前肽明显裂解后,可检测到GAG取代的细胞内核心蛋白。对内切糖苷酶H的敏感性表明,约三分之一的分泌核心蛋白仅含有复合型天冬酰胺连接的寡糖,约三分之二同时含有高甘露糖型和复合型寡糖。分泌的DS-PGII似乎被三条天冬酰胺连接的寡糖链完全取代。然而,寡糖加工抑制剂允许分泌被部分加工的天冬酰胺连接的碳水化合物链完全(三条链)或不完全(一条或两条链)取代的GAG取代的DS-PGII。通过比较软骨细胞DS-PGII与成纤维细胞DS-PGII,我们得出结论:天冬酰胺连接的碳水化合物链的添加和加工由核心蛋白的氨基酸序列指导。此处报道的结果还表明,木糖的添加作为GAG链合成的起始步骤,在生物合成早期发生,并且由核心蛋白的初级氨基酸序列决定。(摘要截短于400字)